Kyntra Bio stock fell to USD 4.85 on October 16, down 9.5 percent

Published on 10/17/2026 at 19:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Maxim set a USD 35.00 target on October 13, 2026. Kyntra Bio stock stood at USD 4.85 on October 16, 2026, down 9.5 percent on Nasdaq.

Analyst targets and cash position

Maxim Group initiated coverage with a USD 35.00 target on October 13, 2026.
Kyntra Bio reported USD 52.70 million in cash and investments for the second quarter of 2026.
Kyntra Bio stock stood at USD 4.85 on October 16, 2026 at 4:00 p.m. ET, down 9.51 percent versus the Nasdaq prior close of October 15, 2026.
Kyntra Bio had a market capitalization of USD 19.6 million and a P/E ratio of 0.08 as of October 16, 2026.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio (ISIN US31572Q8814) fell to USD 4.85 on Nasdaq on October 16, 2026, down 9.51 percent from the prior close of USD 5.36. The move gives the stock report a clear price focus, while a fresh analyst target and the company's cash position provide the main investor context. Investing.com reported on October 13, 2026 that Maxim Group began coverage with a Buy rating and a USD 35.00 price target.

Cash position shapes the outlook

Kyntra Bio reported USD 52.70 million in cash and investments for the second quarter of 2026, according to the October 13, 2026 report. The same report said the company was running a quarterly cash burn of USD 10.00 million, putting liquidity at the center of the valuation discussion.

The financial statements for the second quarter of 2026 show revenue of negative USD 1.47 million, compared with USD 3.74 million in the first quarter. Net income was USD 11.97 million in the second quarter after a net loss of USD 15.13 million in the first quarter. Those figures are sequential comparisons, not year-over-year growth.

Stock sits at the yearly low

The USD 4.85 Nasdaq price matched the 52-week low of USD 4.85 on October 16, 2026. The 52-week high was USD 11.65, leaving the stock 58.37 percent below that level. Trading volume reached 28,497 shares against an average volume of 19,350 shares on the same date.

Kyntra Bio is a biotechnology company developing treatments in oncology and rare diseases. Its principal programs include the FG-3246 antibody-drug conjugate and roxadustat, while the company also carries a research focus on hypoxia-inducible factors and connective tissue growth factor.

How valuation compares with cash

Kyntra Bio had a market capitalization of USD 19.6 million and a P/E ratio of 0.08 as of October 16, 2026. The low market value relative to the USD 52.70 million cash and investments figure reflects a balance sheet comparison, not a valuation recommendation.

The latest dated analyst action came from Maxim Group on October 13, 2026. Its USD 35.00 target stands USD 30.15 above the Nasdaq price of USD 4.85, equal to 621.65 percent above that price. The report also described an ongoing Phase 2 trial with interim data expected in the fourth quarter of 2026.

Nasdaq price and investor context

Kyntra Bio's October 16, 2026 decline places the stock at its 52-week low, while the cash figure and the USD 35.00 analyst target point to two very different ways of assessing the company. The next clearly dated clinical milestone in the cited coverage is interim Phase 2 data expected in the fourth quarter of 2026.

The last available Nasdaq price was USD 4.85 on October 16, 2026 at 4:00 p.m. ET, down 9.51 percent versus the prior close of October 15, 2026 at USD 5.36.